|
|
|
|
|
|
|
01.07.26 - 00:01
|
Nike Appoints Pfizer CFO as New Finance Chief Amid Industry Experience Questions (Bloomberg)
|
|
|
Nina Trentmann, Senior Editor at Bloomberg News, discussed the recent appointment of Dave Denton, formerly Pfizer's CFO, as Nike's new Finance Chief. While some analysts have expressed concerns about Denton's lack of direct retail and apparel industry experience, Trentmann noted that for large companies like Nike and Pfizer, deep industry knowledge may be less critical than experience managing a complex, global business with a significant market capitalization and extensive supply chains. She speaks with Romaine Bostick & Katie Greifeld on "The Close." (Source: Bloomberg)...
|
|
|
30.06.26 - 18:18
|
Wall Street Walked Away From This Powerhouse Stock, But I Am Buying It on Repeat (24/7 Wall St.)
|
|
|
I keep buying Pfizer (NYSE:PFE) every time my brokerage cash builds up, and I am not slowing down. The market is treating this company like a value trap because COVID revenue is rolling off. I am treating it like a cash machine that just bought itself three extra years of patent life on one of ... Wall Street Walked Away From This Powerhouse Stock, But I Am Buying It on Repeat...
|
|
|
30.06.26 - 15:54
|
This 7% Yielding Healthcare Powerhouse Belongs in Retirees′ Portfolios (24/7 Wall St.)
|
|
|
Few large-cap dividends generate as much skepticism as Pfizer (NYSE:PFE). The stock trades at $24.37, and the COVID franchise erosion has been brutal, with Comirnaty down 59% and Paxlovid down 63% in Q1 2026. Yet the dividend keeps coming. I want to know if that 7.27% yield is a gift or a warning. The Dividend ... This 7% Yielding Healthcare Powerhouse Belongs in Retirees' Portfolios...
|
|
|
|
|
|
|
29.06.26 - 13:15
|
Pfizer-Aktie: Darum ist sie jetzt ein klarer Kauf (Sharedeals)
|
|
|
Die Aktie des US-Pharmakonzerns Pfizer rückt nach einem Kursrücksetzer wieder stärker in den Fokus einkommensorientierter Anleger. Ausschlaggebend ist vor allem die außergewöhnlich hohe Dividendenrendite von derzeit rund 6,9 Prozent, mit der das Unternehmen deutlich über dem Durchschnitt des breiten US-Aktienmarktes liegt. Während der S&P 500 aktuell lediglich eine Dividendenrendite von rund 1,3 Prozent bietet, zählt […]
The post Pfizer-Aktie: Darum ist sie jetzt ein klarer Kauf first appeared on sharedeals.de....
|
|
|
|
|
|
|
|
|
26.06.26 - 18:06
|
Moderna Is Up 14% Today: Is It Outperforming Other Vaccine Stocks Like Merck and Pfizer? (24/7 Wall St.)
|
|
|
Shares of Moderna (NASDAQ:MRNA) are up 14% to $68 and change in afternoon trading Friday, extending a remarkable run for the mRNA pioneer. Intraday, MRNA stock hit a new 52-week high of $69.29. The rally easily outpaces peer vaccine makers. Merck (NYSE:MRK) stock is up 2% to $128, while Pfizer (NYSE:PFE) stock trades up 2% ... Moderna Is Up 14% Today: Is It Outperforming Other Vaccine Stocks Like Merck and Pfizer?...
|
|
|
|
|
|
|
|
|
25.06.26 - 12:42
|
Leads Biolabs Announces Partner Oblenio Bio′s $62 Million Oversubscribed Series B Financing to Advance Tri-Specific T-Cell Engager LBL‑051 for Autoimmune Diseases into Clinical Development (GlobeNewswire EN)
|
|
|
NANJING, China, June 25, 2026 (GLOBE NEWSWIRE) -- Nanjing Leads Biolabs Co., Ltd. (“Leads Biolabs” or the “Company,” Stock Code: 9887.HK) today announced that its partner company with Aditum Bio, Oblenio Bio (“Oblenio”), has successfully closed an oversubscribed $62 million Series B financing round. The round was led by Pfizer Ventures, with participation from Deep Track Capital, GV, and founding investor Aditum Bio. This milestone significantly advances the clinical development of LBL‑051, Oblenio's sole asset – a CD19×BCMA×CD3 tri‑specific T‑cell engager designed to reset the immune system in patients with severe autoimmune diseases....
|
|
|
|
|
24.06.26 - 21:54
|
Pfizer Declares Third-Quarter 2026 Dividend (Business Wire)
|
|
|
Board of Directors approves quarterly cash dividend of $0.43 per shareNEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) today announced that its board of directors declared a $0.43 third-quarter 2026 dividend on the company's common stock, payable September 1, 2026, to holders of the Common Stock of record at the close of business on July 24, 2026.
Pfizer is committed to maintaining, and over the longer term, growing the dividend, as part of its capital allocation strategy. The third-quarter 2026 cash dividend will be the 351st consecutive quarterly dividend paid by Pfizer.
About Pfizer: Breakthroughs That Change Patients' Lives
At Pfizer, we apply science and our global resources to bring therapies to people that extend and significantly improve their lives. We strive to set the standard for quality, safety and value in the discovery, development and manufacture of health care products, including innovative medicines and vaccines. Every day, Pfizer colleagues work across developed and emerging markets...
|
|
|
|
|
|
Börsentreff auf Facebook |
Börsentreff auf X |
Börsentreff auf Instagram
